Research and development

Although there are many reports of successes with cannabis therapy, when viewed objectively, medical research is still in its infancy. Out of over 100 cannabinoids found in the hemp plant, only two molecules (THC and CBD) have been studied in detail. The interaction of terpenes (which we perceive as an aroma) with the different cannabinoids can also increase bioavailability in humans.

MediCrops will use a large part of the budget for cooperation with medical universities and cancer clinics to advance specialised research, conduct robust studies and unravel the complex workings of the substances contained in the human endocannabinoid system. In doing so, we are, on the one hand, pursuing the goal of expanding the range of therapeutic applications and further increasing acceptance in society, and on the other hand, this research achievement allows us to develop our own, patentable medical preparations and end products that are many times more profitable than the raw product.

Research and development is carried out by the MediCrops Biomedical Technologies AG company, which is based in the Campus Biopôle in Lausanne. Biopôle is the leading campus for life sciences and patient care – a network of innovative companies.

Good Manufacturing Practice (GMP)

Quality and safety must be validated and verified. The production of medicinal products must comply with the highest standard (GMP: Good Manufacturing Practice). Only a handful of companies worldwide currently have such certification. The high level of expenditure and the time-consuming documentation of the work processes are a major barrier for many companies. The MediCrops management team has over two decades of experience in setting up GMP facilities and has been optimally trained for this.